Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study

NCT07284264 · tracked via the Priya Life Science China tracker

Sponsor

Xuanwu Hospital, Beijing

Phase

Observational

Started

2025-08-15

Last updated

2025-12-16

Condition(s) studied

Dementia

Study summary

The investigators propose a stepwise screening approach. The first step involves rapid digital pre-screening of cognitive function through three components: the SCD-9 questionnaire to capture subjective cognitive complaints, a digital cognitive assessment to evaluate objective performance, and a predictive model to estimate future dementia risk in cognitively normal individuals. The second step confirms the presence of AD pathology using blood-based biomarkers, with a head-to-head comparison of multiple novel candidates to identify those with the greatest diagnostic utility.

Eligibility

Sex

ALL

Min age

50 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: 1. adults aged 50 and above; 2. living in community for at least one year and having established medical records; 3. denying a history of cognitive disorders (mild cognitive impairment, dementia, Alzheimer's disease, etc.) and the use of anti-dementia drugs (cholinesterase inhibitors or memantine, etc.); 4. agreeing to participate in the study; 5. individual or their relatives can communicate normally in Chinese. 6. high-risk groups for dementia（including:1. Complaints of cognitive decline and/or statements by the informant;2. History of AD in first-degree relatives;3. Known ApoE e4 carrier.） Exclusion Criteria: 1. Self-reporting or confirmation through inquiry indicates the presence of severe mental disorders, such as bipolar disorder or schizophrenia, etc. 2. Having a disease that makes it impossible to complete the cognitive assessment.

Primary outcome measure(s)

Sensitivity and specificity of the AD-related cognitive impairment screening and diagnosis program. — Baseline

Trial sites (6)

Facility	City	Region	Status
Xuanwu Hospital, Capital Medical University	Beijing	China	Recruiting
Hainan Medical University	Hainan	China	Recruiting
General Hospital of Ningxia Medical University	Ningxiang	China	Recruiting
The First Hospital of China Medical Unversity	Shenyang	China	Recruiting
Shenzhen Center For Chronic Disease Control	Shenzhen	China	Recruiting
Yichun People'S Hospital	Yichun	China	Recruiting

More Xuanwu Hospital, Beijing trials in China

Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease Recruiting

Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment Recruiting

Tranexamic Acid with Intensive Blood Pressure Management in Ultra-Early Intracerebral Hemorrhage Starting soon

Rehabilitation Exercise Against Complications in High-risk Elderly After Lumbar Fusion(REACH) Recruiting

TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage Recruiting

Other trials for the same condition

Management of Age-Related Auditory Decline and Early Warning of Its Co-occurring Dementia Starting soon

Smartphone Multimodal Health Intervention for Neurological Enhancement (SHINE) Starting soon

Exploring the Diagnostic Biomarkers of Cognitive Disorders in China Recruiting

Cognitive Impairment Cohort Study of the Elderly Population in SheMountain Starting soon

Laser Acupuncture for Behavioral and Psychological Symptoms of Dementia Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07284264 on ClinicalTrials.gov ↗ ← All trials in China